MTOR and neoplasm: For example, if genomic information from the primary tumour was used to inform therapeutic decision-making for patients 63 and 160 (Figures 3 and 4), the AKT1 and ERBB2 amplifications would not have been evident and these patients would not have been considered for HER2 or AKT-mTOR pathway directed therapies.